News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scientific Digital Imaging plc's Synoptics Health Appoints Six Distributors in Asia-Pacific Region



6/24/2013 10:17:11 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cambridge, UK: Scientific Digital Imaging [SDI’s] Synoptics Health Division, a manufacturer of innovative digital imaging systems for healthcare applications is pleased to announce the appointment of distributors throughout the Asia-Pacific region. These new distributors will ensure sterile services department (SSD) personnel in hospitals here can easily access Synoptics Health’s unique ProReveal system, a highly sensitive in-situ fluorescence-based test to detect nanogram levels of protein contamination on surgical instruments.

In just six months, Synoptics Health has appointed six new distributors including Ruhof China, (www.ruhofchina.com) covering China and Taiwan, GSI Creos Corporation in Japan, In Vitro Technologies (www.invitro.com/au) in Australia, PharmaTech Inc in South Korea (www.pharmatech.co.kr), V-Bio Science (www.v-bioscience.com) in Malaysia and Lab Focus Co Ltd (www.labfocus.co.th) in Thailand. Under the terms of the agreements, distributors will market and support Synoptics Health’s ProReveal portfolio of products, which includes the ProReveal viewer and fluorescence testing kits in their assigned regions.

Synoptics Health distributors are organising ProReveal seminars for SSD personnel in over 50 hospitals across the Asia-Pacific region during 2013. During these seminars, Synoptics Health experts will introduce the ProReveal technology and present trial data, to show that ProReveal’s protein detection is around 100 times more sensitive than tests currently being used in SSDs.

Paul Ellwood, SDI Synoptics Health’s CEO explained: “The need to improve the decontamination processes used in hospitals world-wide is currently a major issue since dirty instruments can result in costly hospital closures and more importantly, can lead to patients being infected. The ProReveal technology launched in 2012 is the only commercial test that will meet new upcoming Department of Health guidelines on minimum safe protein contamination levels and using this test in hospitals in the Asia-Pacific region will ensure that surgical instruments are being properly checked for contamination from proteins such as prions that cause vCJD.”

Mike Creedon SDI’s Chief Executive Officer, added: “Asia-Pacific is a rapidly developing region for healthcare products and we’re delighted that companies specialising in this sector have recognised ProReveal’s benefits. This has allowed us in just six months to build an extensive network of partners and we’re also looking to add further distributors here. Since SDD personnel in this region are keen to enhance the quality of their instrument decontamination processes, the potential market for ProReveal is huge and if widely adopted could significantly improve infection control for thousands of patients undertaking surgical operations in hospitals throughout the Asia-Pacific region.”

For Further Information Contact:

Jayne Arthur, Synoptics Health, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.

Tel: +44(0) 1223-727114 Fax +44 (0) 1223-727101

Email: jayne.arthur@synopticshealth.com Web site: www.synopticshealth.com Editor Contact: Dr Sue Pearson, Director, International Science Writer, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK. Tel/Fax +44 (0) 1462-635327 Email: sue.pearson@internationalsciencewriter.com Web: www.internationalsciencewriter.com Twitter:@isciencewriter

About Synoptics Health

Synoptics Health, based in Cambridge, UK is a division of the Synoptics Group of the AIM listed Scientific Digital Imaging (SDI) Company based in Cambridge, UK. Synoptics is a world-leader in the development and manufacture of innovative digital imaging systems for a range of life science applications. The Group has three other divisions, Syngene, Syncroscopy and Synbiosis of which Syngene is the largest.

Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels and has systems in all the major pharmas and academic institutes world-wide. Synoptics’ other divisions Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively. SDI’s Synoptics Group was founded in 1986 and currently employs 45 people, 20 of whom are based at Synoptics Inc. in the USA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES